Status:
COMPLETED
Rhabdomyolysis - a Study of Patients and Laboratory Values to Guide Treatment
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Lovisenberg Diakonale Hospital
Diakonhjemmet Hospital
Conditions:
Rhabdomyolysis
Eligibility:
All Genders
18+ years
Brief Summary
Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the cir...
Detailed Description
Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the cir...
Eligibility Criteria
Inclusion
- Main study:
- Patients age 18 years and older, with a muscle injury developed before hospitalization and serum CK activity ≥5000 U/L and/or serum myoglobin concentrations ≥1000 ng/ml within 72 hours after admission will be included.
Exclusion
- Patients with unknown identity will be excluded.
- Sub-study on rhabdomyolysis and cardiac enzymes:
- Inclusion Criteria: All patients with troponins over 14 ng/L and who otherwise fulfills the inclusion criteria can be included.
Key Trial Info
Start Date :
August 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 22 2023
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT04118608
Start Date
August 4 2019
End Date
December 22 2023
Last Update
March 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital, Ullevaal
Oslo, Norway, 0450